Avalyn Pharma Inc.

Avalyn Pharma Inc. is focused on developing innovative inhaled therapies aimed at treating rare respiratory diseases, specifically targeting pulmonary fibrosis and interstitial lung diseases. Avalyn Pharma Inc. was founded in 2011 and is headquartered in Seattle, US.

The company specializes in developing targeted therapies for rare respiratory conditions. In April 2026, Avalyn Pharma Inc. raised USD 300 million in an IPO, selling 16. 7 million shares at USD 18 per share within the expected USD 16-18 range, on the Nasdaq Global Select Market under the ticker symbol "AVLN.

" Avalyn Pharma Inc. has granted the underwriters a 30-day option to purchase up to an additional 41. 8 million shares of common stock as part of the listing. Following the transaction, F-Prime Capital retained a 5.

46% minority stake, Eventide Asset Management retained a 3. 50% minority stake, Norwest Venture Partners retained a 5. 07% minority stake, Novo Holdings retained a 7. 96% minority stake, Perceptive Advisors retained a 5.

38% minority stake, SR One retained a 6. 58% minority stake, Vida Ventures retained a 3. 05% minority stake, and Wellington Management retained a 3. 05% minority stake in Avalyn Pharma Inc.

, respectively. Avalyn Pharma Inc. develops targeted inhaled therapies for rare respiratory diseases, concentrating on pulmonary fibrosis and interstitial lung diseases. Its core products include AP01, an inhaled formulation of pirfenidone, and AP02, an inhaled version of nintedanib.

Additionally, the company is working on a preclinical program, AP03, which combines both inhaled pirfenidone and nintedanib in a fixed-dose formulation, aiming to deliver effective treatment directly to lung tissue. Avalyn Pharma Inc. generates revenue through partnerships with healthcare providers, focusing on the sale of its inhaled drug products. The company enters agreements with hospitals and specialized clinics for the administration of its inhaled therapies for pulmonary fibrosis, often including provisions for bulk purchases or exclusive supply contracts.

Its flagship products, AP01 and AP02, form the foundation of its revenue model, with pricing aligned to therapeutic value and clinical outcomes.